NCCN Guidelines for Patients® | Chronic Myeloid Leukemia

58 NCCN Guidelines for Patients ® : Chronic Myeloid Leukemia, 2018 Index Index 2 nd opinion 46 accelerated phase 12, 36–37 BCR-ABL1 gene 10–11, 15, 17, 20, 34 blast phase 11–12, 34, 36–37, 39 bone marrow cytogenetics 17, 31 chemotherapy 22–24, 26, 36–39 chronic phase 11–12, 28–32, 36–37 clinical trial 25–26, 28, 36–38, 43 hematopoietic cell transplant (HCT) 24, 26, 31–32, 34, 36–38 International Scale (IS) 17, 29, 30–31, 36, 38 milestone 29–32 NCCN Member Institutions 57 NCCN Panel Members 56 monitoring 29–32 molecular response 29 Philadelphia chromosome 10–12, 15, 17, 29, 31, 38 quantitative reverse transcriptase polymerase chain reaction (QPCR) 15, 17, 29–31, 36, 38 shared decision-making 41, 47 side effect 21, 23–25, 28, 32, 43 supportive care 23 tyrosine kinase inhibitor (TKI) 20–23, 26, 28, 30–32, 36–39

RkJQdWJsaXNoZXIy MTE3MTE1